Corticotropin-releasing factor and defensive withdrawal: Inhibition of monoamine oxidase prevents habituation to chronic stress

Pharmacology Biochemistry and Behavior

Volumn 60, Issue 1, 1998, Pages 209-215

  Ward, Herbert E ^a   Johnson, Elizabeth A ^a   Goodman, Irving J ^a   Birkle, Dale L ^a   Cottrell, Dominic J ^a   Azzaro, Albert J ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Amygdala; Antidepressant; Anxiety; Behavior; Chronic stress; Corticotropin releasing factor; CRF; Defensive withdrawal; MAO; Monoamine oxidase inhibitor; Phenelzine; Rat

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR; MONOAMINE OXIDASE INHIBITOR; PHENELZINE;

ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HABITUATION; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STRESS; SUBCUTANEOUS DRUG ADMINISTRATION;

AMYGDALA; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; CORTICOTROPIN-RELEASING HORMONE; HABITUATION, PSYCHOPHYSIOLOGIC; INJECTIONS, INTRAVENTRICULAR; MALE; MODELS, PSYCHOLOGICAL; MONOAMINE OXIDASE INHIBITORS; PHENELZINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STRESS;

ANIMALIA; GYMNOMYZA SAMOENSIS;

EID: 0032077313     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(97)00580-7     Document Type: Article

References (62)

1. Ahlers S. T., Salander M. K. Effects of repeated administration of corticotropin-releasing factor on schedule-controlled behavior in rats. Pharmacol. Biochem. Behav. 44:1993;375-380.
2. Andrews N., File S. E. Handling history of rats modifies behavioural effects of drugs in the elevated plus-maze test of anxiety. Eur. J. Pharmacol. 235:1993;109-112.
3. Baldesserini R. J. Chemotherapy in psychiatry. 1985;University Press, Cambridge.
4. Ballenger J. C., Burrows G. D., DuPont R. L., Fesser I. M., Noyes R. J., Pecknold J. C., Rifkin A., Swinson R. P. Alprazolam in panic disorder and agorophobia. Results from a multicenter trial Arch. Gen. Psychol. 45:1988;413-422.
5. Bergstrom R. F., Lemberger L., Farid N. A., Wolen R. L. Clinical pharmacology and pharmacokinetics of fluoxetine. A review Br. J. Psychol. 153:1988;47-50.
6. Blier P., De Montigny C., Azzaro A. J. Modification of serotonergic and noradrenergic neurotransmissions by repeated administration of monoamine oxidase inhibitors. Electrophysiological studies in the rat central nervous system J. Pharmacol. Exp. Ther. 237:1986;987-994.
7. Boix F., Teruel A. F., Tobeña A. The anxiolytic action of benzodiazepines is not present in handling-habituated rats. Pharmacol. Biochem. Behav. 31:1989;541-546.
8. Brady L. S., Gold P. W., Herkenham M., Lynn A. B., Whitfield H. J., Jr. The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain. Therapeutic implications Brain Res. 572:1992;117-125.
9. Cancela L. M., Bregonzio C., Molina V. A. Anxiolytic-like effect induced by chronic stress is reversed by naloxone pretreatment. Brain Res. Bull. 36:1994;209-213.
10. Cooper J. R., Bloom F. E., Roth R. H. Cellular foundations of neuropharmacology. The biochemical basis of neuropharmacology. 1991;7-47 Oxford University Press, New York.
11. Coplan J. D., Gorman J. M., Klein D. F. Serotonin related functions in panic-anxiety. A critical overview Neuropsychopharmacology. 6:1992;189-200.
12. Coplan J. D., Tiffon L., Gorman J. M. Therapeutic strategies for the patient with treatment resistant anxiety. J. Clin. Psychol. 54:1993;69-74.
13. Cratty M. S., Ward H. E., Johnson E. A., Azzaro A. J., Birkle D. L. Prenatal stress increases corticotropin-releasing factor (CRF) content and release in rat amygdala minces. Brain Res. 675:1995;297-302.
14. Curtis A. L., Valentino R. J. Corticotropin-releasing factor neurotransmission in locus coeruleus. A possible site of antidepressant action Brain Res. Bull. 35:1994;581-587.
15. Davis M. The role of the amygdala in fear and anxiety. Annu. Rev. Neurosci. 15:1992;353-375.
16. De Souza E. B. Corticotrophin-releasing factor receptors in the rat central nervous system. Characterization and regional distribution J. Neurosci. 7:1987;88-100.
17. De Souza E. B., Insel T. R., Perrin M. H., Rivier J., Vale W., Kuhar M. J. Corticotropin-releasing factor receptors are widely distributed within the rat central nervous system. An autoradiographic study J. Neurosci. 5:1985;3189-3203.
18. Dunn A. J., Berridge C. W. Physiological and behavioral responses to corticotropin-releasing factor administration. Is CRF a mediator of anxiety or stress responses? Brain Res. Rev. 15:1990;71-100.
19. Elkabir D. R., Wyatt M. E., Vellucci S. V., Herbert J. The effects of separate or combined infusions of corticotrophin-releasing factor and vasopressin either intraventricularly or into the amygdala on aggressive and investigative behaviour in the rat. Regul. Pept. 28:1990;199-214.
20. File S. E. The rat corticosterone response. Habituation and modification by chlordiazepoxide Physiol. Behav. 29:1982;91-95.
21. Gao B., Cutler M. G. Effects of acute and chronic administration of the antidepressants, imipramine, phenelzine, and mianserin, on the social behaviour of mice. Neuropharmacology. 33:1994;813-824.
22. Goeders N. E., Bienvenu O. J., De Souza E. B. Chronic cocaine administration alters cortiocotropin-releasing factor receptors in the rat brain. Brain Res. 531:1990;322-328.
23. Gold P. W., Goodwin F. K., Chrousos G. P. Clinical and biochemical manifestations of depression. Relation to neurobiology of stress. N. Engl. J. Med. 319:1988;348-353.
24. Grigoriadis D. E., De Souza E. B. The brain corticotropin-releasing factor (CRF) receptor is of lower apparent molecular weight than the CRF receptor in anterior pituitary. Evidence from crosslinking studies J. Biol. Chem. 263:1988;10927-10931.
25. Hauger R. L., Irwin M. R., Lorang M., Aguilera G., Brown M. R. High intracerebral levels of CRH result in CRH receptor downregulation in the amygdala and neuroimmune desensitization. Brain Res. 616:1993;283-292.
26. Hauger R. L., Lorang M., Irwin M., Aguilera G. CRF receptor regulation and sensitization of ACTH responses to acute ether stress during chronic intermittent immobilization stress. Brain Res. 532:1990;34-40.
27. Hauger R. L., Millan M. A., Lorang M., Harwood J. P., Aguilera G. Corticotropin-releasing factor receptors and pituitary adrenal responses during immobilization stress. Endocrinology. 123:1988;396-405.
28. Johnston A. L., File S. E. Profiles of the antipanic compounds, triazolobenzodiazepines and phenelzine, in two animal tests of anxiety. Psychiatr. Res. 25:1988;81-90.
29. Koob G. F., Heinrichs S. C., Pich E. M., Menzaghi F., Baldwin H., Miczek K., Britton K. T. The role of corticotropin-releasing factor in behavioural responses to stress. Chadwick D. J., Marsh J., Ackrill K. Corticotropin-releasing factor. 1992;277-295 John Wiley and Sons, New York.
30. Kovachich G. B., Frazer A., Aronson C. E. Effect of chronic administration of antidepressants on alpha 2-adrenoceptors in the locus coeruleus and its projection fields in rat brain determined by quantitative autoradiography. Neuropsychopharmacology. 8:1993;57-65.
31. Liang H. C., Lee E. H. Y. Intra-amygdala injections of corticotropin-releasing factor facilitate inhibitory avoidance learning and reduce exploratory behavior in rats. Psychopharmacology (Berlin). 96:1988;232-236.
32. Liebowitz M. R., Fryer A. J., Gorman J. M., Campeas R., Levin A. Phenelzine in social phobia. J. Clin. Psychopharmacol. 6:1986;93-98.
33. Lowry O. H., Rosenbrough N. J., Farr A. L., Randall R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
34. McDougle C. J., Goodman W. K., Price L. H. The pharmacology of obsessive compulsive disorder. Pharmacopsychology. 26:1993;24-29.
35. McKenna K. F., Baker G. B., Coutts R. T., Greenshaw A. J. Chronic administration of antidepressant-antipanic drug phenelzine and its N-acetylated analogue; Effects on monoamine oxidase, biogenic amines, and alpha 2-adrenoreceptor function. J. Pharm. Sci. 81:1992;832-835.
36. Meaney M. J., Mitchell J. B., Aitken D. H., Bhatnagar S., Bodoff S. R., Iny L. J., Sarrieau A. The effects of neonatal handling on the development of the adrenocortical response to stress. Implications for neuropathology and cognitive deficits in later life Psychoneuroendocrinology. 16:1991;85-103.
37. Murua V. S., Molina V. A. Antidepressants reduce inactivity during both inescapable shock administration and shuttle-box testing. Eur. J. Pharmacol. 204:1991;187-192.
38. 125I-iodopindolol to beta-1 adrenoceptors in the amygdala of rat after antidepressant treatments. J. Pharmacol. Exp. Ther. 257:1991;681-690.
39. Owens M. J., Bissette G., Nemeroff C. B. Acute effects of alprazolam and adinazolam on the concentrations of corticotropin-releasing factor in the rat brain. Synapse. 4:1989;196-202.
40. Paetsch P. R., Baker G. B., Greenshaw A. J. Induction of functional downregulation of beta-adrenoceptors in rats by 2-phenylethylamine. J. Pharm. Sci. 82:1993;22-24.
41. Paxinos G., Watson C. The rat brain in stereotaxic coordinates. 1982;Academic Press, New York.
42. Pihoker C., Nemeroff C. B., Owens M. J., Bissette B., Weiss J. M., Krishnan K. R. The role of corticotropin releasing factor (CRF) in the pathogenesis of anxiety and affective disorders. Preclinical and clinical studies Kvetnansky R., McCarty R., Axelrod J. Stress. Neuroendocrine and molecular approaches:1992;915-925 Gordon and Breach Science Publishers, New York.
43. Rassnick S., Heinrichs S. C., Britton K. T., Koob G. F. Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res. 605:1993;25-32.
44. Robinson D. S., Nies A., Ravaris C. L., Ives J. O., Bartlett D. Clinical pharmacology of phenelzine. Arch. Gen. Psychol. 35:1978;629-635.
45. Roy-Byrne P., Wingerson D., Cowley D., Dager S. Psychopharmacologic treatment of panic, generalized anxiety disorder, and social phobia. Psychol. Clin. North Am. 16:1993;719-735.
46. Rudorfer M. V. Monoamine oxidase inhibitors. Reversible and irreversible Psychopharmacol. Bull. 28:1992;45-57.
47. Sawchenko P. E., Swanson L. W. Localization, co-localization, and plasticity of corticotropin-releasing factor immunoreactivity in rat brain. Fed. Proc. 44:1985;221-227.
48. Schatzberg A. F. Overview of anxiety disorders. Prevalence, biology, course, and treatment J. Clin. Psychol. (Suppl.). 52:1991;5-9.
49. Sulser F., Vetulani J., Mobley P. L. Mode of action of antidepressant drugs. Biochem. Pharmacol. 27:1978;257-261.
50. Swanson L. W., Sawchenko P. E., Rivier J., Vale W. Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain. An immunohistochemical study Neuroendocrinology. 36:1983;165-186.
51. Swiergiel A. H., Takahashi L. K., Kalin N. H. Attenuation of stress-induced behavior by antagonism of corticotropin-releasing factor receptors in the central amygdala in the rat. Brain Res. 623:1993;229-234.
52. Takahashi L. K., Kalin N. H., Vanden Burgt J. A., Sherman J. E. Corticotropin-releasing factor modulates defensive-withdrawal and exploratory behavior in rats. Behav. Neurosci. 103:1989;648-654.
53. Tulloch I. F., Johnson A. M. The pharmacological profile of paroxetine, a new selective serotonin reuptake inhibitor. J. Clin. Psychol. (Suppl.). 53:1992;7-12.
54. Tyrer P., Candy J., Kelly D. Phenelzine in phobic anxiety. A controlled trial Psychol. Med. 3:1973;121-124.
55. Uhde T. W., Tancer M. E., Black B., Brown T. M. Phenomenology and neurobiology of social phobia. Comparison with panic disorder J. Clin. Psychol. (Suppl.). 52:1991;31-40.
56. Vale W., Spiess J., Rivier J. Characterization of a 41 amino acid residue ovine hypothalamic peptide that stimulates the secretion of corticotropin and beta-endorphin. Science. 213:1981;1394-1397.
57. Valentino R., Curtis A. L. Antidepressant interactions with corticotropin-releasing factor in the noradrenergic nucleus locus coeruleus. Psychopharmacol. Bull. 27:1991;263.
58. Valentino R. J., Foote S. L., Aston-Jones G. Corticotropin-releasing factor activates noradrenergic neurons of the locus coeruleus. Brain Res. 270:1983;363-367.
59. Yang X., Dunn A. J. Central β1-adrenergic receptors are involved in CRF-induced defensive withdrawal. Pharmacol. Biochem. Behav. 36:1990;847-851.
60. Yang X. M., Gorman A. L., Dunn A. J. The involvement of central noradrenergic systems and corticotropin-releasing factor in defensive-withdrawal behavior in rats. J. Pharmacol. Exp. Ther. 255:1990;1064-1070.
61. Zhu X. O., McNaughton N. Effects of long-term administration of antidepressants on septal driving of hippocampal RSA. Int. J. Neurosci. 79:1994;91-98.
62. Zhu X. O., McNaughton N. Effects of long-term administration of phenelzine on reticular-elicited hippocampal rhythmical slow activity. Neurosci. Res. 21:1995;311-316.